Login / Signup

Echinochrome A Treatment Alleviates Fibrosis and Inflammation in Bleomycin-Induced Scleroderma.

Gyu Tae ParkJung-Won YoonSang-Bin YooYoung-Chul SongParkyong SongHyoung-Kyu KimJin HanSung-Jin BaeKi-Tae HaNatalia P MishchenkoSergey A FedoreyevValentin A StonikMoon-Bum KimJae-Ho Kim
Published in: Marine drugs (2021)
Scleroderma is an autoimmune disease caused by the abnormal regulation of extracellular matrix synthesis and is activated by non-regulated inflammatory cells and cytokines. Echinochrome A (EchA), a natural pigment isolated from sea urchins, has been demonstrated to have antioxidant activities and beneficial effects in various disease models. The present study demonstrates for the first time that EchA treatment alleviates bleomycin-induced scleroderma by normalizing dermal thickness and suppressing collagen deposition in vivo. EchA treatment reduces the number of activated myofibroblasts expressing α-SMA, vimentin, and phosphorylated Smad3 in bleomycin-induced scleroderma. In addition, it decreased the number of macrophages, including M1 and M2 types in the affected skin, suggesting the induction of an anti-inflammatory effect. Furthermore, EchA treatment markedly attenuated serum levels of inflammatory cytokines, such as tumor necrosis factor-α and interferon-γ, in a murine scleroderma model. Taken together, these results suggest that EchA is highly useful for the treatment of scleroderma, exerting anti-fibrosis and anti-inflammatory effects.
Keyphrases
  • systemic sclerosis
  • anti inflammatory
  • interstitial lung disease
  • multiple sclerosis
  • combination therapy
  • drug induced
  • idiopathic pulmonary fibrosis
  • dendritic cells
  • stress induced
  • tissue engineering